Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential

International Journal of Biological Macromolecules

Volumn 81, Issue , 2015, Pages 467-476

  Hansraj, Girotra Priti ^a   Singh, Shailendra Kumar ^a   Kumar, Pawan ^a  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Chitosan; Migraine; Optimization

Indexed keywords

CHITOSAN; PLACEBO; SOLID LIPID NANOPARTICLE; SUMATRIPTAN SUCCINATE; DRUG CARRIER; NANOPARTICLE; SEROTONIN 1 AGONIST; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MIGRAINE; MOUSE; NONHUMAN; PARTICLE SIZE; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT; WRITHING TEST; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; MEDICINAL CHEMISTRY; METABOLISM; MIGRAINE DISORDERS; RAT; ULTRASTRUCTURE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG LIBERATION; MALE; MICE; MIGRAINE DISORDERS; NANOPARTICLES; RATS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUMATRIPTAN; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 84952646236     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.08.035     Document Type: Article

References (37)

1. Girotra P., Singh S.K., Saini D. Disentangling the intricacies of migraine: a review. CNS Neurol. Disord. Drug Targets 2014, 13:776-791.
2. Shrivastava P.S. Challenges in the simultaneous quantitation of Sumatriptan and naproxen in human plasma: Application to a bioequivalence study. J. Chromatogr. B 2012, 902:122-131.
3. Tfelt-Hansen P., Iversen H.K., Olesen J. Subcutaneous sumatriptan in acute migraine. JAMA 1991, 266:2703-2704.
4. Hilaire M.L., Cross L.B., Eichner S.F. Treatment of migraine headaches with sumatriptan in pregnancy. Ann. Pharmacother. 2004, 38:1726-1730.
5. Kolev P. Migraine: principles of acute treatment and prevention. Eur. Neuropsychopharmacol. 2007, 17:S134.
6. Levy D., Jakubowski M., Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4274-4279.
7. Silberstein S.D. Practice parameter: evidence based guidelines for migraine headache (an evidence-based review). Neurology 2000, 55:754-763.
8. Tfelt-Hansen P.C. Does sumatriptan cross the blood-brain barrier in animals and man?. J Headache Pain 2010, 11:5-12.
9. Jagdale S.C., Pawar C.R. Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. BioMed. Res. Int. 2014, 547242:1-10.
10. Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J., Baber N.S. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 1991, 31:291-294.
11. Cheng K.N., Redrup M.J., Barrow A., Williams P.N. Validation of a liquid chromatographic tandem mass spectrometric method for the determination of sumatriptan in human biological fluids. J. Pharm. Biomed. Anal. 1998, 17:399-408.
12. Kaube H., Hoskin K.L., Goadsby P.J. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. 1993, 109:788-792.
13. Nagpal K., Singh S.K., Mishra D.N. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Exp. Opin. Drug Deliv. 2013, 10:927-955.
14. Prasanna R.I., Anitha P., Chetty C.M. Formulation and evaluation of bucco-adhesive tablets of sumatriptan succinate. Int. J. Pharm. Investig. 2011, 1:182-191.
15. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47:65-81.
16. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr. Med. Chem. Cent. Nerv. Syst. Agents 2002, 2:241-249.
17. Deshpande M.V. Enzymatic degradation of chitin and its biological applications. J. Sci. Ind. Res. 1986, 45:273-281.
18. Nagpal K., Singh S.K., Mishra D.N. Evaluation of safety and efficacy of brain targeted chitosan nanoparticles of minocycline. Int. J. Biol. Macromol. 2013, 59:20-28.
19. Wilson B., Samanta M.K., Muthu M.S., Vinothapooshan G. Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease. Ther. Deliv. 2011, 2:599-609.
20. Sarvaiya J., Agrawal Y.K. Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery. Int. J. Biol. Macromol. 2015, 72:454-465.
21. Bowman K., Leong K.W. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed. 2006, 1:117-128.
22. Nair R., Kumar A.C.K., Priya V.K., Yadav C.M., Raju P.Y. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids Health Dis. 2012, 11:72.
23. Niazi S.K. Handbook of Pharmaceutical Manufacturing Formulations - Compressed Solid Products 2009, CRC Press, U.S. second ed.
24. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications 1997, Marcel Dekker, New York. third ed.
25. Majithiya R.J., Majithiya J.B., Umrethia M.L., Ghosh P.K.Y., Murthy R.S.R. HPLC method for the determination of sumatriptan in plasma and brain tissue. Ars. Pharm. 2006, 47:199-210.
26. Galeotti N., Ghelardini C., Grazioli I., Uslenghi C. Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine. Pharmacol. Res. 2002, 46:245-250.
27. Recober A., Kuburas A., Zhang Z., Wemmie J.A., Anderson M.G., Russo A.F. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J. Neurosci. 2009, 29:8798-8804.
28. Russo A.F., Kuburas A., Kaiser E.A., Raddant A.C., Recober A. A potential preclinical migraine model: CGRP-sensitized mice. Mol. Cell Pharmacol. 2009, 1:264-270.
29. Reddy L.H., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.R. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004, 6:55-64.
30. Ritger P.L., Peppas N.A. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 1987, 5:37-42.
31. Fazil M., Md S., Haque S., Kumar M., Baboota S., Sahni J.K., Ali J. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 2012, 47:6-15.
32. Wasutrasawat P., Al-Obaidi H., Gaisford S., Lawrence M.J., Warisnoicharoen W. Drug solubilisation in lipid nanoparticles containing high melting point triglycerides. Eur. J. Pharm. Biopharm. 2013, 85:365-371.
33. Kou L., Sun J., Zhai Y., He Z. The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J. Pharm. Sci. 2013, 8:1-10.
34. Nikai T., Basbaum A.I., Ahn A.H. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain 2008, 139:533-540.
35. Bartsch T., Knight Y.E., Goadsby P.J. Activation of 5-HT (1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann. Neurol. 2004, 56:371-381.
36. Okamoto K., Thompson R., Tashiro A., Chang Z., Bereiter D.A. Bright light produces Fos-positive neurons in caudal trigeminal brainstem. Neuroscience 2009, 160:858-864.
37. Vijayan L., Bansal D., Ray S.B. Nimodipine down-regulates CGRP expression in the rat trigeminal nucleus caudalis. Ind. J. Exp. Biol. 2012, 50:320-324.